LT3558955T - Benzizotiazolo, izotiazolo[3,4-b]piridazino ir ftalazino, pirido[2,3-d] piridazino ir pirido[2,3-d]pirimidino dariniai, kaip kras g12c inhibitoriai, skirti plaučių, kasos arba storosios žarnos vėžio gydymui - Google Patents

Benzizotiazolo, izotiazolo[3,4-b]piridazino ir ftalazino, pirido[2,3-d] piridazino ir pirido[2,3-d]pirimidino dariniai, kaip kras g12c inhibitoriai, skirti plaučių, kasos arba storosios žarnos vėžio gydymui

Info

Publication number: LT3558955T
Authority: LT; Lithuania
Prior art keywords: pyrido; isothiazolo; benzisothiazole; kras; phthalazine
Prior art date: 2016-12-22

Application number

LTEPPCT/US2017/067801T

Other languages

English (en)

Inventor

Brian Alan Lanman

Victor J. Cee

Alexander J. Pickrell

Anthony B. Reed

Kevin C. Yang

David John Kopecky

Hui-Ling Wang

Patricia Lopez

Kate Ashton

Shon Booker

Christopher M. Tegley

Original Assignee

Amgen Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-12-22

Filing date

2017-12-21

Publication date

2021-11-10

2017-12-21 Application filed by Amgen Inc. filed Critical Amgen Inc.

2021-11-10 Publication of LT3558955T publication Critical patent/LT3558955T/lt

Links

CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 title 1
206010009944 Colon cancer Diseases 0.000 title 1
208000001333 Colorectal Neoplasms Diseases 0.000 title 1
206010058467 Lung neoplasm malignant Diseases 0.000 title 1
206010061902 Pancreatic neoplasm Diseases 0.000 title 1
RVKNSWDZQDXTPZ-UHFFFAOYSA-N [1,2]thiazolo[3,4-b]pyridine Chemical compound N1=CC=CC2=CSN=C21 RVKNSWDZQDXTPZ-UHFFFAOYSA-N 0.000 title 1
XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
210000004072 lung Anatomy 0.000 title 1
201000005202 lung cancer Diseases 0.000 title 1
208000020816 lung neoplasm Diseases 0.000 title 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 title 1
201000002528 pancreatic cancer Diseases 0.000 title 1
208000008443 pancreatic carcinoma Diseases 0.000 title 1
LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 title 1
GIVUQTUKKWDKHE-UHFFFAOYSA-N pyrido[2,3-d]pyridazine Chemical compound C1=NN=CC2=CC=CN=C21 GIVUQTUKKWDKHE-UHFFFAOYSA-N 0.000 title 1
159000000018 pyrido[2,3-d]pyrimidines Chemical class 0.000 title 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

LTEPPCT/US2017/067801T 2016-12-22 2017-12-21 Benzizotiazolo, izotiazolo[3,4-b]piridazino ir ftalazino, pirido[2,3-d] piridazino ir pirido[2,3-d]pirimidino dariniai, kaip kras g12c inhibitoriai, skirti plaučių, kasos arba storosios žarnos vėžio gydymui LT3558955T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662438334P	2016-12-22	2016-12-22
PCT/US2017/067801 WO2018119183A2 (en)	2016-12-22	2017-12-21	Kras g12c inhibitors and methods of using the same

Publications (1)

Publication Number	Publication Date
LT3558955T true LT3558955T (lt)	2021-11-10

Family

ID=61007802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEPPCT/US2017/067801T LT3558955T (lt)	2016-12-22	2017-12-21	Benzizotiazolo, izotiazolo[3,4-b]piridazino ir ftalazino, pirido[2,3-d] piridazino ir pirido[2,3-d]pirimidino dariniai, kaip kras g12c inhibitoriai, skirti plaučių, kasos arba storosios žarnos vėžio gydymui

Country Status (34)

Country	Link
US (3)	US10532042B2 (lt)
EP (2)	EP3558955B1 (lt)
JP (4)	JP6858861B2 (lt)
KR (2)	KR20230150408A (lt)
CN (3)	CN116621833A (lt)
AU (2)	AU2017379074C9 (lt)
BR (1)	BR112019012976A2 (lt)
CA (1)	CA3048217A1 (lt)
CL (2)	CL2019001762A1 (lt)
CO (1)	CO2019006598A2 (lt)
CR (1)	CR20190338A (lt)
CY (1)	CY1125262T1 (lt)
DK (1)	DK3558955T3 (lt)
EA (1)	EA201991528A1 (lt)
ES (1)	ES2894255T3 (lt)
HR (1)	HRP20211642T1 (lt)
HU (1)	HUE056777T2 (lt)
IL (2)	IL267495B (lt)
JO (1)	JOP20190154B1 (lt)
LT (1)	LT3558955T (lt)
MA (1)	MA47107B1 (lt)
MX (1)	MX2019007643A (lt)
MY (1)	MY196830A (lt)
NZ (1)	NZ754994A (lt)
PE (1)	PE20191207A1 (lt)
PH (1)	PH12019501670A1 (lt)
PL (1)	PL3558955T3 (lt)
PT (1)	PT3558955T (lt)
RS (1)	RS62456B1 (lt)
SG (2)	SG11201906223TA (lt)
SI (1)	SI3558955T1 (lt)
UA (1)	UA124474C2 (lt)
WO (1)	WO2018119183A2 (lt)
ZA (1)	ZA201904548B (lt)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2863873T3 (es)	2016-05-18	2021-10-11	Mirati Therapeutics Inc	Inhibidores de KRAS G12C
KR20230150408A (ko) *	2016-12-22	2023-10-30	암젠 인크	폐암, 췌장암 또는 대장암을 치료하기 위한 kras g12c 억제제로서의 벤즈이소티아졸, 이소티아졸로[3,4-b]피리딘, 퀴나졸린, 프탈라진, 피리도[2,3-d]피리다진 및 피리도[2,3-d]피리미딘 유도체
JOP20190272A1 (ar)	2017-05-22	2019-11-21	Amgen Inc	مثبطات kras g12c وطرق لاستخدامها
TWI731264B (zh) *	2017-09-08	2021-06-21	美商安進公司	Kras g12c抑制劑以及其使用方法
JOP20180094A1 (ar)	2017-10-18	2019-04-18	Hk Inno N Corp	مركب حلقي غير متجانس كمثبط بروتين كيناز
US10647715B2 (en)	2017-11-15	2020-05-12	Mirati Therapeutics, Inc.	KRas G12C inhibitors
US10689377B2 (en)	2017-11-15	2020-06-23	Mirati Therapeutics, Inc.	KRas G12C inhibitors
US11453667B2 (en)	2018-01-19	2022-09-27	Medshine Discovery Inc.	Pyridone-pyrimidine derivative acting as KRASG12C mutein inhibitor
CA3099118A1 (en)	2018-05-04	2019-11-07	Amgen Inc.	Kras g12c inhibitors and methods of using the same
JP7266043B2 (ja) *	2018-05-04	2023-04-27	アムジエン・インコーポレーテツド	ＫＲａｓＧ１２Ｃ阻害剤及びそれを使用する方法
WO2019217307A1 (en)	2018-05-07	2019-11-14	Mirati Therapeutics, Inc.	Kras g12c inhibitors
TW202012415A (zh)	2018-05-08	2020-04-01	瑞典商阿斯特捷利康公司	化學化合物
MA52564A (fr)	2018-05-10	2021-03-17	Amgen Inc	Inhibiteurs de kras g12c pour le traitement du cancer
JP7360396B2 (ja)	2018-06-01	2023-10-12	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤及び同一物の使用方法
US11285156B2 (en)	2018-06-12	2022-03-29	Amgen Inc.	Substituted piperazines as KRAS G12C inhibitors
CA3104654A1 (en)	2018-06-27	2020-01-02	Bristol-Myers Squibb Company	Substituted naphthyridinone compounds useful as t cell activators
KR20210024587A (ko)	2018-06-27	2021-03-05	브리스톨-마이어스 스큅 컴퍼니	T 세포 활성화제로서 유용한 나프티리디논 화합물
KR102495687B1 (ko)	2018-08-16	2023-02-07	에프. 호프만-라 로슈 아게	융합 고리 화합물
WO2020055758A1 (en) *	2018-09-10	2020-03-19	Mirati Therapeutics, Inc.	Combination therapies
CN112996795A (zh)	2018-09-18	2021-06-18	尼坎医疗公司	作为src同源-2磷酸酶抑制剂的稠合的三环衍生物
JP2020090482A (ja)	2018-11-16	2020-06-11	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
MA55136A (fr)	2018-11-19	2022-02-23	Amgen Inc	Inhibiteurs de kras g12c et leurs procédés d'utilisation
JP7377679B2 (ja) *	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
MX2021006841A (es) *	2018-12-10	2021-07-02	Ideaya Biosciences Inc	Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2?.
EP3908283A4 (en)	2019-01-10	2022-10-12	Mirati Therapeutics, Inc.	KRAS G12C INHIBITORS
EP4249000A3 (en)	2019-02-12	2023-12-27	Novartis AG	Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
CN113474340A (zh)	2019-02-26	2021-10-01	勃林格殷格翰国际有限公司	作为ras抑制剂的新型异吲哚啉酮取代的吲哚和衍生物
CN111773225A (zh) *	2019-04-04	2020-10-16	山东轩竹医药科技有限公司	Kras及其突变体表达抑制剂
EP3738593A1 (en)	2019-05-14	2020-11-18	Amgen, Inc	Dosing of kras inhibitor for treatment of cancers
WO2020234103A1 (en)	2019-05-21	2020-11-26	Bayer Aktiengesellschaft	Identification and use of kras inhibitors
BR112021023136A2 (pt) *	2019-05-21	2022-01-04	Inventisbio Co Ltd	Compostos heterocíclicos, métodos de preparação e usos dos mesmos
JP7092935B2 (ja)	2019-05-21	2022-06-28	アムジエン・インコーポレーテツド	固体形態
CN113423703A (zh) *	2019-05-29	2021-09-21	上海翰森生物医药科技有限公司	含氮杂环类衍生物调节剂、其制备方法和应用
CN112047937B (zh) *	2019-06-06	2023-04-07	劲方医药科技(上海)有限公司	四氢吡啶并[3,4-d]嘧啶-2(1H)-酮类化合物，其制法与医药上的用途
JP2022539341A (ja) *	2019-06-24	2022-09-08	クヮントンニューオップバイオファーマシューティカルズカンパニー，リミテッド	Ｋｒａｓｇ１２ｃの阻害剤としての複素環式化合物
CN110256421A (zh) *	2019-06-26	2019-09-20	微境生物医药科技(上海)有限公司	Kras-g12c抑制剂
CN112300173B (zh) *	2019-07-30	2021-10-01	上海凌达生物医药有限公司	一类含氮多环类化合物、制备方法和用途
US20220298174A1 (en) *	2019-08-02	2022-09-22	Shanghai Jemincare Pharmaceuticals Co., Ltd	Tetracyclic compound, preparation method therefor and use thereof
TWI752580B (zh) *	2019-08-07	2022-01-11	大陸商北京加科思新藥研發有限公司	Kras突變蛋白抑制劑
AR119821A1 (es)	2019-08-28	2022-01-12	Bristol Myers Squibb Co	Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
US11453683B1 (en)	2019-08-29	2022-09-27	Mirati Therapeutics, Inc.	KRas G12D inhibitors
JP2022548791A (ja)	2019-09-24	2022-11-21	ミラティセラピューティクス，インコーポレイテッド	組み合わせ療法
WO2021057832A1 (en) *	2019-09-25	2021-04-01	Jacobio Pharmaceuticals Co., Ltd.	Kras mutant protein inhibitor
EP4045047A1 (en)	2019-10-15	2022-08-24	Amgen Inc.	Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
JP2022552873A (ja)	2019-10-24	2022-12-20	アムジエン・インコーポレーテツド	がんの治療におけるｋｒａｓｇ１２ｃ及びｋｒａｓｇ１２ｄ阻害剤として有用なピリドピリミジン誘導体
MX2022005053A (es)	2019-10-28	2022-05-18	Merck Sharp & Dohme Llc	Inhibidores de peque?as moleculas de mutante g12c de kras.
US11608346B2 (en)	2019-11-04	2023-03-21	Revolution Medicines, Inc.	Ras inhibitors
CA3159559A1 (en)	2019-11-04	2021-05-14	Revolution Medicines, Inc.	Ras inhibitors
JP2022553858A (ja)	2019-11-04	2022-12-26	レボリューションメディシンズインコーポレイテッド	Ｒａｓ阻害剤
JP2023505100A (ja)	2019-11-27	2023-02-08	レボリューションメディシンズインコーポレイテッド	共有ｒａｓ阻害剤及びその使用
CN111377918B (zh) *	2019-11-29	2021-03-02	苏州信诺维医药科技有限公司	一种kras抑制剂化合物
US20230028414A1 (en)	2019-12-16	2023-01-26	Amgen Inc.	Dosing regimen of kras g12c inhibitor
WO2021120045A1 (en)	2019-12-18	2021-06-24	InventisBio Co., Ltd.	Heterocyclic compounds, preparation methods and uses thereof
WO2021120890A1 (en)	2019-12-20	2021-06-24	Novartis Ag	Pyrazolyl derivatives useful as anti-cancer agents
MX2022007515A (es)	2019-12-20	2022-09-19	Mirati Therapeutics Inc	Inhibidores de sos1.
AR120823A1 (es)	2019-12-23	2022-03-23	Bristol Myers Squibb Co	Compuestos bicíclicos sustituidos útiles como activadores de células t
CN114671866A (zh) *	2020-12-25	2022-06-28	苏州泽璟生物制药股份有限公司	芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
WO2021150613A1 (en)	2020-01-20	2021-07-29	Incyte Corporation	Spiro compounds as inhibitors of kras
GB202001344D0 (en)	2020-01-31	2020-03-18	Redx Pharma Plc	Ras Inhibitors
CN112159405B (zh) *	2020-02-04	2021-09-14	广州必贝特医药技术有限公司	吡啶并嘧啶酮类化合物及其应用
CN113248521B (zh) *	2020-02-11	2023-07-18	上海和誉生物医药科技有限公司	一种k-ras g12c抑制剂及其制备方法和应用
US20230143751A1 (en) *	2020-02-24	2023-05-11	Shanghai Zheye Biotechnology Co. Ltd.	Aromatic Compound And Use Thereof In Preparing Antineoplastic Drugs
CN114901663A (zh) *	2020-03-02	2022-08-12	上海喆邺生物科技有限公司	一类芳香杂环类化合物及其在药物中的应用
CN111358794A (zh) *	2020-03-13	2020-07-03	南通大学	一种用于治疗非小细胞肺癌的药物或试剂盒
TW202144345A (zh)	2020-03-17	2021-12-01	大陸商北京加科思新藥研發有限公司	Ｋｒａｓ突變蛋白抑制劑
JP7461499B2 (ja) *	2020-04-03	2024-04-03	メッドシャインディスカバリーインコーポレイテッド	オクタヒドロピラジノジアザナフチリジンジオン化合物
US11739102B2 (en)	2020-05-13	2023-08-29	Incyte Corporation	Fused pyrimidine compounds as KRAS inhibitors
CN112574199B (zh) *	2020-05-20	2021-05-18	首药控股(北京)股份有限公司	Kras-G12C抑制剂杂环化合物
US11945812B2 (en) *	2020-06-02	2024-04-02	Boehringer Ingelheim International Gmbh	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TW202210633A (zh)	2020-06-05	2022-03-16	法商昂席歐公司	用於治療癌症之dbait分子與kras抑制劑的組合
WO2021249563A1 (zh) *	2020-06-12	2021-12-16	苏州泽璟生物制药股份有限公司	芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
EP4168002A1 (en)	2020-06-18	2023-04-26	Revolution Medicines, Inc.	Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
TW202214608A (zh) *	2020-07-20	2022-04-16	大陸商江蘇恆瑞醫藥股份有限公司	稠合噠嗪類衍生物、其製備方法及其在醫藥上的應用
EP4194452A1 (en) *	2020-08-02	2023-06-14	Shanghai Zheye Biotechnology Co., Ltd.	Aromatic compound and application thereof in antitumor drug
CN114075195A (zh) *	2020-08-21	2022-02-22	广东东阳光药业有限公司	嘧啶酮衍生物及其在药物中的应用
KR102560912B1 (ko)	2020-08-26	2023-07-28	한양대학교 에리카산학협력단	엑소좀을 유효성분으로 포함하는 폐암 치료, 예방 또는 전이 억제용 약학적 조성물
WO2022047093A1 (en) *	2020-08-28	2022-03-03	Incyte Corporation	Vinyl imidazole compounds as inhibitors of kras
MX2023002248A (es)	2020-09-03	2023-05-16	Revolution Medicines Inc	Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
CR20230165A (es)	2020-09-15	2023-06-02	Revolution Medicines Inc	Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
WO2022068921A1 (zh) *	2020-09-30	2022-04-07	上海医药集团股份有限公司	一种喹唑啉类化合物及其应用
WO2022072783A1 (en)	2020-10-02	2022-04-07	Incyte Corporation	Bicyclic dione compounds as inhibitors of kras
TW202227438A (zh) *	2020-11-24	2022-07-16	大陸商杭州多域生物技術有限公司	一種芳香化合物、其製備方法及應用
WO2022121839A1 (zh) *	2020-12-08	2022-06-16	上海和誉生物医药科技有限公司	吡啶并[2,3-d]嘧啶-2(1H)-酮衍生物及其制备方法和应用
WO2022127847A1 (zh) *	2020-12-17	2022-06-23	广东东阳光药业有限公司	嘧啶酮衍生物及其在药物中的应用
WO2022133345A1 (en)	2020-12-18	2022-06-23	Erasca, Inc.	Tricyclic pyridones and pyrimidones
US20240100172A1 (en)	2020-12-21	2024-03-28	Hangzhou Jijing Pharmaceutical Technology Limited	Methods and compounds for targeted autophagy
CN116648250A (zh) *	2020-12-22	2023-08-25	韩美药品株式会社	作为sos1抑制剂的新型喹唑啉衍生物及其用途
AU2021409561A1 (en)	2020-12-22	2023-07-06	Nikang Therapeutics, Inc.	Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
CN115124533A (zh) *	2021-03-26	2022-09-30	浙江海正药业股份有限公司	四环类衍生物、其制备方法和其医药上的用途
WO2022221528A2 (en) *	2021-04-16	2022-10-20	Mirati Therapeutics, Inc.	Kras g12c inhibitors
BR112023022819A2 (pt)	2021-05-05	2024-01-16	Revolution Medicines Inc	Compostos, composição farmacêutica, conjugados e métodos para tratar câncer em um sujeito, para tratar um distúrbio e para inibir uma proteína ras em uma célula
CN117616031A (zh)	2021-05-05	2024-02-27	锐新医药公司	用于治疗癌症的ras抑制剂
WO2022266206A1 (en)	2021-06-16	2022-12-22	Erasca, Inc.	Kras inhibitor conjugates
TW202317100A (zh)	2021-06-23	2023-05-01	瑞士商諾華公司	包含ｋｒａｓｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
IL308165A (en)	2021-06-23	2024-01-01	Novartis Ag	Pyrazolyl derivatives as inhibitors of the mutant Kras protein
TW202317589A (zh)	2021-07-14	2023-05-01	美商尼坎醫療公司	作為ｋｒａｓ抑制劑的伸烷基衍生物
CA3224341A1 (en)	2021-09-01	2023-03-09	Novartis Ag	Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
AU2022349569A1 (en)	2021-09-22	2024-04-04	Sichuan Huiyu Pharmaceutical Co., Ltd.	Pyridine derivative and use thereof
AR127308A1 (es)	2021-10-08	2024-01-10	Revolution Medicines Inc	Inhibidores ras
WO2023064857A1 (en)	2021-10-14	2023-04-20	Incyte Corporation	Quinoline compounds as inhibitors of kras
TW202334089A (zh)	2021-11-02	2023-09-01	美商夫雷爾醫療公司	Ｐｐａｒｇ反向激動劑及其用途
WO2023099592A1 (en) *	2021-12-01	2023-06-08	Boehringer Ingelheim International Gmbh	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023114954A1 (en)	2021-12-17	2023-06-22	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
CN116332960A (zh) *	2021-12-23	2023-06-27	上海优理惠生医药有限公司	一种哒嗪类化合物、其药物组合物及应用
WO2023152255A1 (en)	2022-02-10	2023-08-17	Bayer Aktiengesellschaft	Fused pyrimidines as kras inhibitors
EP4227307A1 (en)	2022-02-11	2023-08-16	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en)	2022-03-08	2023-09-14	Revolution Medicines, Inc.	Methods for treating immune refractory lung cancer
US20230303509A1 (en)	2022-03-28	2023-09-28	Nikang Therapeutics, Inc.	Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
WO2023194310A1 (en)	2022-04-04	2023-10-12	Sanofi	Therapeutic combination of kras g12c inhibitor and tead inhibitor
WO2023199180A1 (en)	2022-04-11	2023-10-19	Novartis Ag	Therapeutic uses of a krasg12c inhibitor
WO2023240024A1 (en)	2022-06-08	2023-12-14	Nikang Therapeutics, Inc.	Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
WO2023240253A2 (en) *	2022-06-10	2023-12-14	Forward Therapeutics, Inc.	Modulators of tnf-alpha activity
WO2023240263A1 (en)	2022-06-10	2023-12-14	Revolution Medicines, Inc.	Macrocyclic ras inhibitors
WO2024040131A1 (en)	2022-08-17	2024-02-22	Treeline Biosciences, Inc.	Pyridopyrimidine kras inhibitors
GB202212641D0 (en)	2022-08-31	2022-10-12	Jazz Pharmaceuticals Ireland Ltd	Novel compounds

Family Cites Families (205)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4450150A (en)	1973-05-17	1984-05-22	Arthur D. Little, Inc.	Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4232027A (en)	1979-01-29	1980-11-04	E. R. Squibb & Sons, Inc.	1,2-Dihydro-2-oxo-4-phenyl-3-quinolinecarbonitrile derivatives
DE3381783D1 (de)	1982-03-03	1990-09-13	Genentech Inc	Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen.
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
GB8827305D0 (en)	1988-11-23	1988-12-29	British Bio Technology	Compounds
JP2762522B2 (ja)	1989-03-06	1998-06-04	藤沢薬品工業株式会社	血管新生阻害剤
US5112946A (en)	1989-07-06	1992-05-12	Repligen Corporation	Modified pf4 compositions and methods of use
PT98990A (pt)	1990-09-19	1992-08-31	American Home Prod	Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5892112A (en)	1990-11-21	1999-04-06	Glycomed Incorporated	Process for preparing synthetic matrix metalloprotease inhibitors
US5120842A (en)	1991-04-01	1992-06-09	American Home Products Corporation	Silyl ethers of rapamycin
US5100883A (en)	1991-04-08	1992-03-31	American Home Products Corporation	Fluorinated esters of rapamycin
US5118678A (en)	1991-04-17	1992-06-02	American Home Products Corporation	Carbamates of rapamycin
EP0584222B1 (en)	1991-05-10	1997-10-08	Rhone-Poulenc Rorer International (Holdings) Inc.	Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5118677A (en)	1991-05-20	1992-06-02	American Home Products Corporation	Amide esters of rapamycin
NZ243082A (en)	1991-06-28	1995-02-24	Ici Plc	4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US5151413A (en)	1991-11-06	1992-09-29	American Home Products Corporation	Rapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en)	1991-12-03	1992-01-29	Smithkline Beecham Plc	Novel compound
AU661533B2 (en)	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
US5521184A (en)	1992-04-03	1996-05-28	Ciba-Geigy Corporation	Pyrimidine derivatives and processes for the preparation thereof
ZA935111B (en)	1992-07-17	1994-02-04	Smithkline Beecham Corp	Rapamycin derivatives
ZA935112B (en)	1992-07-17	1994-02-08	Smithkline Beecham Corp	Rapamycin derivatives
US5256790A (en)	1992-08-13	1993-10-26	American Home Products Corporation	27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en)	1992-10-09	1992-11-25	Sandoz Ag	Organic componds
US5258389A (en)	1992-11-09	1993-11-02	Merck & Co., Inc.	O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
JP3560609B2 (ja)	1992-11-13	2004-09-02	イミュネックス・コーポレーション	Ｅｌｋリガンドと呼ばれる新規なサイトカイン
US5455258A (en)	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
US5629327A (en)	1993-03-01	1997-05-13	Childrens Hospital Medical Center Corp.	Methods and compositions for inhibition of angiogenesis
US5516658A (en)	1993-08-20	1996-05-14	Immunex Corporation	DNA encoding cytokines that bind the cell surface receptor hek
US5612340A (en)	1993-10-01	1997-03-18	Ciba-Geigy Corporation	Pyrimidineamine derivatives and processes for the preparation thereof
US5656643A (en)	1993-11-08	1997-08-12	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0729471A1 (en)	1993-11-19	1996-09-04	Abbott Laboratories	Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
DE69423781T2 (de)	1993-12-17	2000-08-10	Novartis Ag	Rapamycin-derivate als immunosuppressoren
US5700823A (en)	1994-01-07	1997-12-23	Sugen, Inc.	Treatment of platelet derived growth factor related disorders such as cancers
IL112249A (en)	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en)	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
AU2096895A (en)	1994-03-07	1995-09-25	Sugen, Incorporated	Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
EP1464706A3 (en)	1994-04-15	2004-11-03	Amgen Inc.,	HEK5, HEK7, HEK8, HEK11, EPH-like receptor protein tyrosine kinases
DK0682027T3 (da)	1994-05-03	1998-05-04	Ciba Geigy Ag	Pyrrolopyrimidinderivater med antiproliferativ virkning
US6303769B1 (en)	1994-07-08	2001-10-16	Immunex Corporation	Lerk-5 dna
US5919905A (en)	1994-10-05	1999-07-06	Immunex Corporation	Cytokine designated LERK-6
US6057124A (en)	1995-01-27	2000-05-02	Amgen Inc.	Nucleic acids encoding ligands for HEK4 receptors
US5863949A (en)	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
WO1996030347A1 (en)	1995-03-30	1996-10-03	Pfizer Inc.	Quinazoline derivatives
DK0819129T3 (da)	1995-04-03	2000-10-23	Novartis Ag	Pyrazolderivater og fremgangsmåde til deres fremstilling
CA2218503C (en)	1995-04-20	2001-07-24	Pfizer Inc.	Arylsulfonyl hydroxamic acid derivatives
GB9508538D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
US5747498A (en)	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en)	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
US5650415A (en)	1995-06-07	1997-07-22	Sugen, Inc.	Quinoline compounds
DE69624921T2 (de)	1995-06-09	2003-09-11	Novartis Ag	Rapamycinderivate
CZ1598A3 (cs)	1995-07-06	1998-04-15	Novartis Ag	Pyrrolopyrimidiny a způsoby jejich přípravy
DE19534177A1 (de)	1995-09-15	1997-03-20	Merck Patent Gmbh	Cyclische Adhäsionsinhibitoren
AR004010A1 (es)	1995-10-11	1998-09-30	Glaxo Group Ltd	Compuestos heterociclicos
GB9523675D0 (en)	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
ATE225343T1 (de)	1995-12-20	2002-10-15	Hoffmann La Roche	Matrix-metalloprotease inhibitoren
EP0888349B1 (en)	1996-01-23	2002-05-22	Novartis AG	Pyrrolopyrimidines and processes for their preparation
JP3406763B2 (ja)	1996-01-30	2003-05-12	東レ・ダウコーニング・シリコーン株式会社	シリコーンゴム組成物
GB9603097D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline compounds
GB9603095D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
DE19629652A1 (de)	1996-03-06	1998-01-29	Thomae Gmbh Dr K	4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19608588A1 (de)	1996-03-06	1997-09-11	Thomae Gmbh Dr K	Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
BR9709443B1 (pt)	1996-03-15	2009-05-05		n-7-heterociclil-pirrol[2,3-d]pirimidinas, bem como composições farmacêuticas compreendendo as mesmas.
CN100503580C (zh)	1996-04-12	2009-06-24	沃尼尔·朗伯公司	酪氨酸激酶的不可逆抑制剂
GB9607729D0 (en)	1996-04-13	1996-06-19	Zeneca Ltd	Quinazoline derivatives
BR9709959A (pt)	1996-06-24	2000-05-09	Pfizer	Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
EP0937082A2 (en)	1996-07-12	1999-08-25	Ariad Pharmaceuticals, Inc.	Materials and method for treating or preventing pathogenic fungal infection
EP0818442A3 (en)	1996-07-12	1998-12-30	Pfizer Inc.	Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
HRP970371A2 (en)	1996-07-13	1998-08-31	Kathryn Jane Smith	Heterocyclic compounds
DE69716916T2 (de)	1996-07-13	2003-07-03	Glaxo Group Ltd	Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
BR9710362A (pt)	1996-07-13	1999-08-17	Glaxo Group Ltd	Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto
DE69712496T2 (de)	1996-07-18	2002-08-29	Pfizer	Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren
US6111090A (en)	1996-08-16	2000-08-29	Schering Corporation	Mammalian cell surface antigens; related reagents
EP1947183B1 (en)	1996-08-16	2013-07-17	Merck Sharp & Dohme Corp.	Mammalian cell surface antigens; related reagents
DK0938486T3 (da)	1996-08-23	2008-07-07	Novartis Ag	Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
KR20000068248A (ko)	1996-08-23	2000-11-25	디. 제이. 우드, 스피겔 알렌 제이	아릴설포닐아미노 하이드록삼산 유도체
AU4779897A (en)	1996-10-02	1998-04-24	Novartis Ag	Fused pyrazole derivatives and processes for their preparation
ID18494A (id)	1996-10-02	1998-04-16	Novartis Ag	Turunan pirazola leburan dan proses pembuatannya
WO1998014450A1 (en)	1996-10-02	1998-04-09	Novartis Ag	Pyrimidine derivatives and processes for the preparation thereof
EP0837063A1 (en)	1996-10-17	1998-04-22	Pfizer Inc.	4-Aminoquinazoline derivatives
GB9621757D0 (en)	1996-10-18	1996-12-11	Ciba Geigy Ag	Phenyl-substituted bicyclic heterocyclyl derivatives and their use
PT950059E (pt)	1997-01-06	2004-10-29	Pfizer	Derivados de sulfona ciclicos
US6303636B1 (en)	1997-02-03	2001-10-16	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
WO1998033798A2 (en)	1997-02-05	1998-08-06	Warner Lambert Company	Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
AU5493598A (en)	1997-02-07	1998-08-26	Pfizer Inc.	N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
BR9807678A (pt)	1997-02-11	2000-02-15	Pfizer	Derivados de ácidos arilsulfonil-hidroxâmicos
CO4950519A1 (es)	1997-02-13	2000-09-01	Novartis Ag	Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6150395A (en)	1997-05-30	2000-11-21	The Regents Of The University Of California	Indole-3-carbinol (I3C) derivatives and methods
US6329375B1 (en)	1997-08-05	2001-12-11	Sugen, Inc.	Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
CA2299355C (en)	1997-08-08	2005-09-27	Pfizer Products Inc.	Aryloxyarylsulfonylamino hydroxamic acid derivatives
US6509173B1 (en)	1997-10-21	2003-01-21	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
GB9725782D0 (en)	1997-12-05	1998-02-04	Pfizer Ltd	Therapeutic agents
GB9800569D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
GB9800575D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
GB9801690D0 (en)	1998-01-27	1998-03-25	Pfizer Ltd	Therapeutic agents
JP2002502607A (ja)	1998-02-09	2002-01-29	ジェネンテク・インコーポレイテッド	新規な腫瘍壊死因子レセプター相同体及びそれをコードする核酸
WO1999045009A1 (en)	1998-03-04	1999-09-10	Bristol-Myers Squibb Company	Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
PA8469501A1 (es)	1998-04-10	2000-09-29	Pfizer Prod Inc	Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es)	1998-04-10	2000-05-24	Pfizer Prod Inc	Derivados biciclicos del acido hidroxamico
WO1999061422A1 (en)	1998-05-29	1999-12-02	Sugen, Inc.	Pyrrole substituted 2-indolinone protein kinase inhibitors
UA60365C2 (uk)	1998-06-04	2003-10-15	Пфайзер Продактс Інк.	Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
EP1097147A4 (en)	1998-07-10	2001-11-21	Merck & Co Inc	NEW ANGIOGENESIS INHIBITORS
CA2341409A1 (en)	1998-08-31	2000-03-09	Merck And Co., Inc.	Novel angiogenesis inhibitors
EP1004578B1 (en)	1998-11-05	2004-02-25	Pfizer Products Inc.	5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
WO2000041698A1 (en)	1999-01-13	2000-07-20	Bayer Corporation	φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
CA2366857C (en)	1999-03-30	2010-12-14	Novartis Ag	Phthalazine derivatives for treating inflammatory diseases
GB9912961D0 (en)	1999-06-03	1999-08-04	Pfizer Ltd	Metalloprotease inhibitors
US6521424B2 (en)	1999-06-07	2003-02-18	Immunex Corporation	Recombinant expression of Tek antagonists
NZ516258A (en)	1999-06-07	2004-02-27	Immunex Corp	Tek antagonists
DE60036945T2 (de)	1999-07-12	2008-08-21	Genentech, Inc., South San Francisco	Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen
CN1293081C (zh)	1999-08-24	2007-01-03	阿里亚德基因治疗公司	28－表雷帕霉素类似物,其制备方法，药物组合物和用途
DK1676845T3 (da)	1999-11-05	2008-09-15	Astrazeneca Ab	Nye quinazolinderivater
DK1233943T3 (da)	1999-11-24	2011-08-15	Sugen Inc	Ioniserbare indolinon derivater og anvendelse deraf som PTK ligander
US6515004B1 (en)	1999-12-15	2003-02-04	Bristol-Myers Squibb Company	N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6727225B2 (en)	1999-12-20	2004-04-27	Immunex Corporation	TWEAK receptor
AU2001247219B2 (en)	2000-02-25	2007-01-04	Immunex Corporation	Integrin antagonists
US6630500B2 (en)	2000-08-25	2003-10-07	Cephalon, Inc.	Selected fused pyrrolocarbazoles
CZ304059B6 (cs)	2000-12-21	2013-09-11	Glaxo Group Limited	Deriváty pyrimidinu a farmaceutický prostredek
US6995162B2 (en)	2001-01-12	2006-02-07	Amgen Inc.	Substituted alkylamine derivatives and methods of use
US7102009B2 (en)	2001-01-12	2006-09-05	Amgen Inc.	Substituted amine derivatives and methods of use
US6878714B2 (en)	2001-01-12	2005-04-12	Amgen Inc.	Substituted alkylamine derivatives and methods of use
US20020147198A1 (en)	2001-01-12	2002-10-10	Guoqing Chen	Substituted arylamine derivatives and methods of use
US7105682B2 (en)	2001-01-12	2006-09-12	Amgen Inc.	Substituted amine derivatives and methods of use
JP2002233610A (ja)	2002-02-18	2002-08-20	Olympia:Kk	スロットマシン
US7307088B2 (en)	2002-07-09	2007-12-11	Amgen Inc.	Substituted anthranilic amide derivatives and methods of use
TWI329112B (en)	2002-07-19	2010-08-21	Bristol Myers Squibb Co	Novel inhibitors of kinases
KR20060052681A (ko)	2003-05-23	2006-05-19	와이어쓰	Ｇｉｔｒ 리간드, ｇｉｔｒ 리간드-연관 분자, 항체 및그의 용도
ES2316995T3 (es)	2003-07-08	2009-04-16	Novartis Ag	Uso de rapamicina y derivados de rapamicida para el tratamiento de la perdida osea.
WO2005007190A1 (en)	2003-07-11	2005-01-27	Schering Corporation	Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
WO2005016252A2 (en)	2003-07-11	2005-02-24	Ariad Gene Therapeutics, Inc.	Phosphorus-containing macrocycles
TW200523262A (en)	2003-07-29	2005-07-16	Smithkline Beecham Corp	Inhibitors of AKT activity
MXJL06000006A (es)	2003-08-22	2006-05-04	Avanir Pharmaceuticals	Derivados de naftiridina sustituidos como inhibidores del factor inhibidor de la migracion de macrofagos y su uso en el tratamiento de enfermedades en el hombre.
JP2007518399A (ja)	2003-12-02	2007-07-12	ジェンザイムコーポレイション	肺癌を診断および治療する組成物並びに方法
GB0409799D0 (en)	2004-04-30	2004-06-09	Isis Innovation	Method of generating improved immune response
US20060002932A1 (en)	2004-06-04	2006-01-05	Duke University	Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
CN101023064B (zh)	2004-08-26	2011-02-16	辉瑞大药厂	作为蛋白激酶抑制剂的对映异构体纯的氨基杂芳基化合物
GT200500287A (es)	2004-10-13	2006-04-17		Analogos de 17-hidroxiwortmanina como inhibidores de pi3k
DK1866339T3 (da)	2005-03-25	2013-09-02	Gitr Inc	GTR-bindende molekyler og anvendelser heraf
DK2161336T4 (en)	2005-05-09	2017-04-24	Ono Pharmaceutical Co	Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
WO2007034327A1 (en)	2005-09-20	2007-03-29	Pfizer Products Inc.	Dosage forms and methods of treatment using a tyrosine kinase inhibitor
EP1981969A4 (en)	2006-01-19	2009-06-03	Genzyme Corp	ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER
TWI499420B (zh)	2006-12-07	2015-09-11	Hoffmann La Roche	肌醇磷脂３-激酶抑制劑化合物及使用方法
US8591886B2 (en)	2007-07-12	2013-11-26	Gitr, Inc.	Combination therapies employing GITR binding molecules
RU2523890C2 (ru)	2007-09-12	2014-07-27	Дженентек, Инк.	Комбинации ингибиторов фосфоинозитид 3-киназы и химиотерапевтических агентов и способы применения
JP5348725B2 (ja)	2007-10-25	2013-11-20	ジェネンテック，インコーポレイテッド	チエノピリミジン化合物の製造方法
WO2010003118A1 (en)	2008-07-02	2010-01-07	Trubion Pharmaceuticals, Inc.	Tgf-b antagonist multi-target binding proteins
WO2010030002A1 (ja)	2008-09-12	2010-03-18	国立大学法人三重大学	外来性ｇｉｔｒリガンド発現細胞
EP2266984A1 (en) *	2009-06-26	2010-12-29	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Pyrido[2,3-d]pyrimidines as Wnt antagonists for treatment of cancer and arthritis
LT3023438T (lt)	2009-09-03	2020-05-11	Merck Sharp & Dohme Corp.	Anti-gitr antikūnai
GB0919054D0 (en)	2009-10-30	2009-12-16	Isis Innovation	Treatment of obesity
CN102108078B (zh) *	2009-12-24	2013-10-30	沈阳药科大学	1,4-取代酞嗪类化合物及其制备方法和用途
CN105693861A (zh)	2009-12-29	2016-06-22	新兴产品开发西雅图有限公司	异二聚体结合蛋白及其应用
EP2696682B1 (en) *	2011-04-13	2018-03-21	Innovimmune Biotherapeutics, Inc.	Mif inhibitors and their uses
WO2013039954A1 (en)	2011-09-14	2013-03-21	Sanofi	Anti-gitr antibodies
EP2836482B1 (en)	2012-04-10	2019-12-25	The Regents of The University of California	Compositions and methods for treating cancer
MX364438B (es)	2013-03-15	2019-04-26	Araxes Pharma Llc	Inhibidores covalentes de kras g12c.
US9745319B2 (en)	2013-03-15	2017-08-29	Araxes Pharma Llc	Irreversible covalent inhibitors of the GTPase K-Ras G12C
US9227978B2 (en)	2013-03-15	2016-01-05	Araxes Pharma Llc	Covalent inhibitors of Kras G12C
GB201312059D0 (en)	2013-07-05	2013-08-21	Univ Leuven Kath	Novel GAK modulators
JO3805B1 (ar) *	2013-10-10	2021-01-31	Araxes Pharma Llc	مثبطات كراس جي12سي
BR112016008016B8 (pt)	2013-10-10	2023-09-26	Araxes Pharma Llc	Compostos inibidores de kras g12c, composição farmacêutica compreendendo ditos compostos, métodos para regular a atividade e para preparar uma proteína mutante kras, hras ou nras g12c, método para inibir a proliferação de uma população de células e usos terapêuticos dos ditos compostos
GB201320729D0 (en)	2013-11-25	2014-01-08	Cancer Rec Tech Ltd	Therapeutic compounds and their use
BR112016016421B1 (pt) *	2014-01-20	2022-10-18	Cleave Biosciences, Inc	Composto de pirimidina fundida, composição farmacêutica e respectivos uso
JO3556B1 (ar) *	2014-09-18	2020-07-05	Araxes Pharma Llc	علاجات مدمجة لمعالجة السرطان
US10011600B2 (en)	2014-09-25	2018-07-03	Araxes Pharma Llc	Methods and compositions for inhibition of Ras
EP3197870B1 (en)	2014-09-25	2020-08-19	Araxes Pharma LLC	Inhibitors of kras g12c mutant proteins
WO2016049565A1 (en)	2014-09-25	2016-03-31	Araxes Pharma Llc	Compositions and methods for inhibition of ras
EA201792214A1 (ru)	2015-04-10	2018-01-31	Араксис Фарма Ллк	Соединения замещенного хиназолина
ES2856880T3 (es)	2015-04-15	2021-09-28	Araxes Pharma Llc	Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
EP3325447A1 (en)	2015-07-22	2018-05-30	Araxes Pharma LLC	Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
US10882847B2 (en)	2015-09-28	2021-01-05	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
EP3356351A1 (en)	2015-09-28	2018-08-08	Araxes Pharma LLC	Inhibitors of kras g12c mutant proteins
EP3356347A1 (en)	2015-09-28	2018-08-08	Araxes Pharma LLC	Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en)	2015-09-28	2017-04-06	Araxes Pharma Llc	Inhibitors of kras g12c mutant proteins
EP3356354A1 (en)	2015-09-28	2018-08-08	Araxes Pharma LLC	Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en)	2015-09-28	2017-04-06	Araxes Pharma Llc	Inhibitors of kras g12c mutant proteins
EP3356349A1 (en)	2015-09-28	2018-08-08	Araxes Pharma LLC	Inhibitors of kras g12c mutant proteins
AU2016355433C1 (en) *	2015-11-16	2021-12-16	Araxes Pharma Llc	2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
WO2017100546A1 (en)	2015-12-09	2017-06-15	Araxes Pharma Llc	Methods for preparation of quinazoline derivatives
WO2017172979A1 (en)	2016-03-30	2017-10-05	Araxes Pharma Llc	Substituted quinazoline compounds and methods of use
ES2863873T3 (es)	2016-05-18	2021-10-11	Mirati Therapeutics Inc	Inhibidores de KRAS G12C
US10646488B2 (en)	2016-07-13	2020-05-12	Araxes Pharma Llc	Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
EP3519402A1 (en)	2016-09-29	2019-08-07	Araxes Pharma LLC	Inhibitors of kras g12c mutant proteins
JP2019534260A (ja)	2016-10-07	2019-11-28	アラクセスファーマエルエルシー	Ｒａｓの阻害剤としての複素環式化合物およびその使用方法
KR20230150408A (ko) *	2016-12-22	2023-10-30	암젠 인크	폐암, 췌장암 또는 대장암을 치료하기 위한 kras g12c 억제제로서의 벤즈이소티아졸, 이소티아졸로[3,4-b]피리딘, 퀴나졸린, 프탈라진, 피리도[2,3-d]피리다진 및 피리도[2,3-d]피리미딘 유도체
JP2020505395A (ja)	2017-01-26	2020-02-20	アラクセスファーマエルエルシー	縮合ｎ−複素環式化合物およびその使用方法
JOP20190272A1 (ar)	2017-05-22	2019-11-21	Amgen Inc	مثبطات kras g12c وطرق لاستخدامها
US11639346B2 (en)	2017-05-25	2023-05-02	Araxes Pharma Llc	Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
TWI731264B (zh)	2017-09-08	2021-06-21	美商安進公司	Kras g12c抑制劑以及其使用方法
JP7266043B2 (ja)	2018-05-04	2023-04-27	アムジエン・インコーポレーテツド	ＫＲａｓＧ１２Ｃ阻害剤及びそれを使用する方法
CA3099118A1 (en)	2018-05-04	2019-11-07	Amgen Inc.	Kras g12c inhibitors and methods of using the same
MA52564A (fr)	2018-05-10	2021-03-17	Amgen Inc	Inhibiteurs de kras g12c pour le traitement du cancer
JP7360396B2 (ja)	2018-06-01	2023-10-12	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤及び同一物の使用方法
MX2020012204A (es)	2018-06-11	2021-03-31	Amgen Inc	Inhibidores de kras g12c para tratar el cáncer.
US11285156B2 (en)	2018-06-12	2022-03-29	Amgen Inc.	Substituted piperazines as KRAS G12C inhibitors
JP2021528404A (ja)	2018-06-21	2021-10-21	ヤンセンファーマシューティカエヌ．ベー．	Ｏｇａ阻害剤化合物
WO2019243533A1 (en)	2018-06-21	2019-12-26	Janssen Pharmaceutica Nv	Oga inhibitor compounds
JP2020090482A (ja)	2018-11-16	2020-06-11	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
MA55136A (fr)	2018-11-19	2022-02-23	Amgen Inc	Inhibiteurs de kras g12c et leurs procédés d'utilisation
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3738593A1 (en)	2019-05-14	2020-11-18	Amgen, Inc	Dosing of kras inhibitor for treatment of cancers
AU2020277398A1 (en)	2019-05-21	2021-12-09	Amgen Inc.	Solid state forms
JP7092935B2 (ja)	2019-05-21	2022-06-28	アムジエン・インコーポレーテツド	固体形態
JP2022552873A (ja)	2019-10-24	2022-12-20	アムジエン・インコーポレーテツド	がんの治療におけるｋｒａｓｇ１２ｃ及びｋｒａｓｇ１２ｄ阻害剤として有用なピリドピリミジン誘導体
US20230028414A1 (en)	2019-12-16	2023-01-26	Amgen Inc.	Dosing regimen of kras g12c inhibitor

2017
- 2017-12-21 KR KR1020237035546A patent/KR20230150408A/ko active Application Filing
- 2017-12-21 CN CN202310364215.0A patent/CN116621833A/zh active Pending
- 2017-12-21 HR HRP20211642TT patent/HRP20211642T1/hr unknown
- 2017-12-21 CN CN202310364214.6A patent/CN116606261A/zh active Pending
- 2017-12-21 JP JP2019534162A patent/JP6858861B2/ja active Active
- 2017-12-21 WO PCT/US2017/067801 patent/WO2018119183A2/en unknown
- 2017-12-21 NZ NZ754994A patent/NZ754994A/en unknown
- 2017-12-21 AU AU2017379074A patent/AU2017379074C9/en active Active
- 2017-12-21 RS RS20211294A patent/RS62456B1/sr unknown
- 2017-12-21 CN CN201780087190.7A patent/CN110366550A/zh active Pending
- 2017-12-21 LT LTEPPCT/US2017/067801T patent/LT3558955T/lt unknown
- 2017-12-21 EA EA201991528A patent/EA201991528A1/ru unknown
- 2017-12-21 MY MYPI2019004551A patent/MY196830A/en unknown
- 2017-12-21 BR BR112019012976A patent/BR112019012976A2/pt unknown
- 2017-12-21 JO JOP/2019/0154A patent/JOP20190154B1/ar active
- 2017-12-21 DK DK17832646.8T patent/DK3558955T3/da active
- 2017-12-21 EP EP17832646.8A patent/EP3558955B1/en active Active
- 2017-12-21 PE PE2019001307A patent/PE20191207A1/es unknown
- 2017-12-21 PT PT178326468T patent/PT3558955T/pt unknown
- 2017-12-21 PL PL17832646T patent/PL3558955T3/pl unknown
- 2017-12-21 SG SG11201906223TA patent/SG11201906223TA/en unknown
- 2017-12-21 MX MX2019007643A patent/MX2019007643A/es unknown
- 2017-12-21 HU HUE17832646A patent/HUE056777T2/hu unknown
- 2017-12-21 SI SI201730951T patent/SI3558955T1/sl unknown
- 2017-12-21 ES ES17832646T patent/ES2894255T3/es active Active
- 2017-12-21 KR KR1020197020877A patent/KR102592246B1/ko active IP Right Grant
- 2017-12-21 EP EP21183032.8A patent/EP4001269A1/en active Pending
- 2017-12-21 CR CR20190338A patent/CR20190338A/es unknown
- 2017-12-21 SG SG10201913491PA patent/SG10201913491PA/en unknown
- 2017-12-21 UA UAA201908270A patent/UA124474C2/uk unknown
- 2017-12-21 MA MA47107A patent/MA47107B1/fr unknown
- 2017-12-21 US US15/849,905 patent/US10532042B2/en active Active
- 2017-12-21 CA CA3048217A patent/CA3048217A1/en active Pending
2019
- 2019-06-19 IL IL267495A patent/IL267495B/en unknown
- 2019-06-20 CO CONC2019/0006598A patent/CO2019006598A2/es unknown
- 2019-06-21 CL CL2019001762A patent/CL2019001762A1/es unknown
- 2019-07-11 ZA ZA2019/04548A patent/ZA201904548B/en unknown
- 2019-07-18 PH PH12019501670A patent/PH12019501670A1/en unknown
- 2019-11-05 US US16/675,121 patent/US11285135B2/en active Active
2020
- 2020-03-26 CL CL2020000784A patent/CL2020000784A1/es unknown
2021
- 2021-03-24 JP JP2021049530A patent/JP7073554B2/ja active Active
- 2021-10-13 IL IL287223A patent/IL287223B2/en unknown
- 2021-11-02 CY CY20211100937T patent/CY1125262T1/el unknown
2022
- 2022-01-31 US US17/589,163 patent/US20220168280A1/en not_active Abandoned
- 2022-05-10 JP JP2022077379A patent/JP7373014B2/ja active Active
- 2022-06-09 AU AU2022204026A patent/AU2022204026A1/en active Pending
2023
- 2023-10-19 JP JP2023180046A patent/JP2024010022A/ja active Pending

Also Published As

Publication number	Publication date
CR20190338A (es)	2019-09-09
PL3558955T3 (pl)	2021-12-27
US20220168280A1 (en)	2022-06-02
CO2019006598A2 (es)	2019-06-28
JP2020504738A (ja)	2020-02-13
MA47107B1 (fr)	2021-11-30
RS62456B1 (sr)	2021-11-30
AU2022204026A1 (en)	2022-06-30
IL287223A (en)	2021-12-01
WO2018119183A3 (en)	2018-08-23
CN110366550A (zh)	2019-10-22
EA201991528A1 (ru)	2020-01-16
AU2017379074C9 (en)	2023-06-08
US10532042B2 (en)	2020-01-14
JP2021100960A (ja)	2021-07-08
JP6858861B2 (ja)	2021-04-14
EP3558955A2 (en)	2019-10-30
JOP20190154B1 (ar)	2022-09-15
JP7073554B2 (ja)	2022-05-23
MA47107A (fr)	2021-03-31
JP2024010022A (ja)	2024-01-23
KR102592246B1 (ko)	2023-10-23
PT3558955T (pt)	2021-10-19
AU2017379074C1 (en)	2023-05-25
ES2894255T3 (es)	2022-02-14
AU2017379074A1 (en)	2019-07-18
HRP20211642T1 (hr)	2022-01-21
KR20230150408A (ko)	2023-10-30
IL267495B (en)	2021-10-31
IL267495A (en)	2019-08-29
PH12019501670A1 (en)	2019-11-04
ZA201904548B (en)	2020-03-25
MY196830A (en)	2023-05-03
IL287223B1 (en)	2023-04-01
CN116621833A (zh)	2023-08-22
KR20190097201A (ko)	2019-08-20
US11285135B2 (en)	2022-03-29
MX2019007643A (es)	2019-09-09
WO2018119183A2 (en)	2018-06-28
CL2020000784A1 (es)	2020-08-28
SG11201906223TA (en)	2019-08-27
NZ754994A (en)	2022-12-23
SI3558955T1 (sl)	2021-12-31
CA3048217A1 (en)	2018-06-28
BR112019012976A2 (pt)	2019-12-31
DK3558955T3 (da)	2021-10-25
JP2022110053A (ja)	2022-07-28
CL2019001762A1 (es)	2019-10-18
PE20191207A1 (es)	2019-09-10
US20200069657A1 (en)	2020-03-05
US20180177767A1 (en)	2018-06-28
JP7373014B2 (ja)	2023-11-01
HUE056777T2 (hu)	2022-03-28
EP4001269A1 (en)	2022-05-25
EP3558955B1 (en)	2021-08-11
UA124474C2 (uk)	2021-09-22
AU2017379074B2 (en)	2022-03-17
SG10201913491PA (en)	2020-03-30
IL287223B2 (en)	2023-08-01
CN116606261A (zh)	2023-08-18
CY1125262T1 (el)	2023-06-09
JOP20190154A1 (ar)	2019-06-23

Publication	Publication Date	Title
ZA201904548B (en)	2020-03-25	Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
PH12018500792A1 (en)	2018-10-01	Benzolactam compounds as protein kinase inhibitors
IL266245B (en)	2021-05-31	History of 9,8,7,6-tetrahydro-3h-pyrazolo[3,4-f]isoquinoline useful in cancer treatment
HK1255598A1 (zh)	2019-08-23	咪唑並[4，5-c]喹啉-2-酮化合物以及它們在治療癌症中的用途
PH12014501986B1 (en)	2014-11-24	2-amino, 6-phenyl substituted pyrido [2,3-d] pyrimidine derivatives useful as raf kinase inhibitors
EP3268000A4 (en)	2018-08-22	Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
HK1257413A1 (zh)	2019-10-18	用於治療癌症的、為共濟失調毛細血管擴張症突變型(atm)激酶的選擇性調節劑的8-[6-[3-(氨基)丙氧基]-3-吡啶基]-1-異丙基-咪唑並[4，5-c]喹啉-2-酮衍生物
PL3712152T3 (pl)	2021-08-02	Pochodne 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pirydyny i 1,4,5,6,7,8-heksahydroimidazo[4,5-d]azepiny jako inhibitory kinaz janusowych
PT3371185T (pt)	2020-12-28	Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
MY185392A (en)	2021-05-17	Jak1 inhibitors for the treatment of myelodysplastic syndromes
HK1257677A1 (zh)	2019-10-25	咪唑並[4，5-c]喹啉-2-酮化合物以及它們在治療癌症中的用途
IL293093B1 (en)	2024-03-01	The use of pyrimidine and pyridine history in the treatment of cancer
GB201608227D0 (en)	2016-06-22	Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
IL258707A (en)	2018-06-28	6-[5-amino-6-(2-ethoxyethoxy)-imidazo[4,5-b]pyridin-3-yl]-nicotinonitrile derivatives and their use as irak inhibitors
GB201604182D0 (en)	2016-04-27	Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
WO2014153464A3 (en)	2014-11-27	2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer
NZ629877A (en)	2015-12-24	Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use